Evidence map›Paper›PMID 40901444›Full record

ArticleJournal of advanced pharmaceutical technology & research

Dewi Melani Hariyadi, Lubby Razan Fawwaz, Abdul Fattah, Noorma Rosita, Tutiek Purwanti, Tristiana Erawati

Abstract read
In one paragraph

Article in Journal of advanced pharmaceutical technology & research. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

6 authors.

Dewi Melani HariyadiDepartment of Pharmaceutical Sciences, Faculty of Pharmacy, Universitas Airlangga, Surabaya, Indonesia.
Lubby Razan FawwazDepartment of Pharmaceutical Sciences, Faculty of Pharmacy, Universitas Airlangga, Surabaya, Indonesia.
Abdul FattahDepartment of Pharmaceutical Sciences, Faculty of Pharmacy, Universitas Airlangga, Surabaya, Indonesia.
Noorma RositaDepartment of Pharmaceutical Sciences, Faculty of Pharmacy, Universitas Airlangga, Surabaya, Indonesia.
Tutiek PurwantiDepartment of Pharmaceutical Sciences, Faculty of Pharmacy, Universitas Airlangga, Surabaya, Indonesia.
Tristiana ErawatiDepartment of Pharmaceutical Sciences, Faculty of Pharmacy, Universitas Airlangga, Surabaya, Indonesia.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Some antituberculosis drugs were reported to have adverse effects. The study investigates the use of quercetin pulmospheres as an alternative to traditional antituberculosis drugs. Formulated with alginate and kappa carrageenan as F1, F2, and F3 (1:1, 1:2, and 1:3), the pulmospheres were observed for the release and deposition in rat lungs. Results show a sustained release of 50.47% ±0.43%-58.37% ±0.57% in 10 h above minimum inhibitory concentration (MIC) against

Indexed as

Alginatekappa carrageenanlung depositionpulmospheresquercetinrelease

Identifiers

PMID40901444
PMCPMC12401518

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC-SA
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.